Skip to content
Study details
Enrolling now

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Blue Earth Therapeutics Ltd
NCT IDNCT05413850ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1/2

Target enrollment

82

Study length

about 5.7 years

Ages

18+

Sex

Male only

Locations

5 sites in FL, GA, NE +1

What this study is about

Researchers are testing a new treatment, Lutetium (177Lu) rhPSMA-10.1 injection, to see if it can help fight prostate cancer that has spread and become resistant to other treatments. The trial will involve men with advanced prostate cancer who have not responded well to hormone therapy. This is an interventional trial where participants receive the new treatment.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Receive 18F-rhPSMA-7.3 injection (in phase 1 only)
  • 2.Receive Lutetium (177Lu) rhPSMA-10.1 Injection

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IV

How treatment is administered

Treatment Assignment
Randomized (Open Label)

You are randomly assigned, but you will know your treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug routes

injection

Endpoints

Primary: Phase 1 Frequency and nature of TEAEs

Body systems

Oncology